SCHEMBL26776154

SCHEMBL26776154

O=[N+]([O-])c1nc(F)c(Br)cc1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.36
▸ NQO2 P16083 1/20 0.34
▸ RIPK1 Q13546 1/20 0.34
▸ HTT P42858 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CXCR1 P25024 1/20 0.33
▸ CXCR2 P25025 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ CA12 O43570 3/20 0.33
▸ CA1 P00915 3/20 0.33
▸ CA2 P00918 3/20 0.33
▸ CA9 Q16790 3/20 0.33
▸ USP7 Q93009 1/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31728271 0.79 TTR (0.34) MAPTNQO2RIPK1HTTTDP1
SCHEMBL3951274 0.79 S1PR4 (0.35) MAPTNQO2HTTTDP1LMNA
SCHEMBL26776153 0.75 MAPT (0.45) MAPTHTTLMNAMEN1KMT2A
SCHEMBL29560142 0.75 MAPT (0.45) MAPTHTTLMNAMEN1KMT2A
SCHEMBL30977593 0.72 TDP1 (0.42) MAPTHTTTDP1PKMALDH1A1
SCHEMBL31727334 0.71 CYP1A2 (0.37) MAPTHTTTDP1LMNAMEN1
SCHEMBL5582938 0.70 MAPK1 (0.36) MAPTHTTTDP1LMNAMEN1
SCHEMBL2586421 0.70 MAPT (0.41) MAPTHTTTDP1LMNAMEN1
SCHEMBL8159248 0.70 ALDH1A1 (0.43) MAPTTDP1MEN1KMT2ASMN1; SMN2
SCHEMBL1809848 0.68 SMN1; SMN2 (0.37) MAPTHTTTDP1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4649077-A1 SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF Cerevel Therapeutics, LLC (US) 2025-11-19 — — EP disclosed
WO-2024151833-A1 SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF CEREVEL THERAPEUTICS, LLC (US) 2024-07-18 — — WO disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 MAPT 2850/4885NQO2 1536/4885RIPK1 1954/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 MAPT 2850/4885NQO2 1536/4885RIPK1 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback